Address: 1 Institut Pasteur, Phnom Penh, Cambodia, 2 Calmette Hopsital, Phnom Penh, Cambodia, 3 Chey Chaum Neas Hospital, Takamao, Kandal province, Cambodia, 4 Magna Children at Risk, Phnom Penh, Cambodia, 5 NMCHC Hospital, Phnom Penh, Cambodia and 6 EA 3620, Université Paris-Descarte, CHU Necker-Enfants Malades, Paris, France * Corresponding author
Background
In resource constrained settings where prevention of mother to child transmission of HIV-1 (PMTCT) programs are in place, the proportion of residual in utero transmission (rIUT) versus peri partum transmission (PPT) is unknown and the morbidity/mortality related, or not, to MTC transmission of HIV-1, within the first 6 weeks of life, poorly documented.
Main objective
To assess the feasibility and the contribution of the very early diagnosis on Dried Blood Spot (DBS), conducted at day 0-day 3 of age in improving the medical care of HIV-1 exposed newborn within the first 6 weeks of life.
Methods
Very early diagnosis was explained and proposed, before and/or after delivery, to HIV positive mothers delivering at Calmette and hospitals and health centers supported by Magna Children at Risk (NMCHC, Chey Chumneas Hospital and 3 Municipality Health Centers). A first negative HIV-DNA negative DBS at day 0-day 3 was followed up by a second DBS at W6. HIV-DNA positive DBS at d0-d3, or at week 6 were followed up by a venipuncture as soon as possible for HIV-RNA quantification (Kit G2 ANRS) and CD4 count.
Preliminary results
Heel prick blood specimens were spotted on DBS for 272 newborns (ratio M/F = 1.3) at d0-d3. HIV DNA was detected in 3 of 272 babies (rIUT rate: 1.1%). One of them died before week 6. The two others presenting detectable HIV-1 RNA viral loads at week 6 (6.4 and 6.9 log 10 copies/ ml with CD4 at 19% and 21%, respectively) started first line ARV regimen and became HIV-1 RNA undetectable after 10 and 4 months of treatment. Among the 269 HIV-DNA negative newborn at d0-d3, 228 (84.5%) have been already seen at week 6 for virological confirmation, 23 are still waiting for the visit of the week 6, 14 were lost of follow up and 4 died without any AIDS clinical symptoms. 226 of 228 DBS were confirmed HIV-DNA negative at week 6 whereas 2 infants became HIV-DNA positive (PPT rate: 0.8%). Both were confirmed HIV-RNA positive two weeks later (5.8 and 6.2 log 10 copies/ml with CD4 at 33% and 26%, respectively) and will soon begin their ARV treatment.
Discussion
The rIU and PP transmission rates were low in this study (1.1% and 0.8% respectively). 5 new born were diagnosed HIV infected. One died before W6, and 2 already started ARV treatment. Further investigations are undergoing to understand why 14 newborn were lost of follow up. These preliminary results demonstrate the feasibility of a mini- 
